Low-grade serous ovarian cancer (LGSOC) accounts for between 5-10% of all serous ovarian carcinomas [1]. A decade of using the binary grading system for serous carcinoma [2] had to pass until in 2014 the World Health Organization changed the classification system of ovarian cancer in order to differentiate LGSOC and high-grade serous ovarian cancer (HGSOC) as two distinct entities [3]. Clinically, LGSOC is characterized by younger age, indolent clinical course and poor response to conventional chemotherapy, but is not refractory to platinum-based chemotherapy in any setting [1,[4][5]. Immunohistochemically it shows a low Ki-67 proliferation index and high levels of estrogen receptors (ER) compared with HGSOC. TP53 wild-type pattern can be useful to distinguish LGSOC from HGSOC. Genetic profiling has demonstrated frequent BRAF, NRAS, and KRAS mutations, in approximately 50-60% of the cases [6, 7]. This case emphasizes the importance of the knowledge of the tumor biology in order to be able to offer our patients different treatment strategies.
Introduction
Low-grade serous ovarian cancer (LGSOC) accounts for between 5-10% of all serous ovarian carcinomas [1] . A decade of using the binary grading system for serous carcinoma [2] had to pass until in 2014 the World Health Organization changed the classification system of ovarian cancer in order to differentiate LGSOC and high-grade serous ovarian cancer (HGSOC) as two distinct entities [3] . Clinically, LGSOC is characterized by younger age, indolent clinical course and poor response to conventional chemotherapy, but is not refractory to platinum-based chemotherapy in any setting [1, [4] [5] . Immunohistochemically it shows a low Ki-67 proliferation index and high levels of estrogen receptors (ER) compared with HGSOC. TP53 wild-type pattern can be useful to distinguish LGSOC from HGSOC. Genetic profiling has demonstrated frequent BRAF, NRAS, and KRAS mutations, in approximately 50-60% of the cases [6, 7] . This case emphasizes the importance of the knowledge of the tumor biology in order to be able to offer our patients different treatment strategies.
Case description
A 75-year-old woman underwent her annual gynecological review, where transvaginal sonography showed bilateral adnexal mixed solid and cystic masses of 6 × 5 cm and 7 × 5 cm. The patient's medical history included familial hypercholesterolemia and appendectomy in her twenties. Her family history included a sister diagnosed with breast cancer at 60 years of age. Laboratory tests reported a carcinoembryonic antigen (CA)-125 level of of 9407 IU/mL (normal value <32 IU/mL) and CA-15-3 level of 87.5 IU/mL (normal value <35 IU/mL). A positron emission tomography/computed tomography (PET/CT) scan showed a high fluorodeoxyglucose (FDG) avidity pelvic mass of 10 × 10 cm with multiple abdominal-pelvic implants, inguinal, retroperitoneal, bilateral internal mammary and left supraclavicular lymph nodes (Figures 1 and 2) . The case was discussed in the Gynaecological Oncology Multi-Disciplinary Team (MDT) meeting. As the supradiaphragmatic tumor load was low, we considered per- Stage IV low-grade serous ovarian carcinoma management in an elderly patient forming a laparoscopy to confirm the diagnosis in order to evaluate if the patient could benefit from a primary debulking surgery (PDS). The histopathological examination demonstrated lowgrade papillary serous ovarian cancer. Immunohistochemical study revealed tumor cells positive for CK7, WT1 and ER, marked heterogeneity of focally distributed p53-positive cells and a proliferation index Ki-67 between 15-20% ( Figure 3) . With the results obtained, the patient was presented at the MDT again, and it was agreed to perform a PDS. The surgery included modified posterior exenteration with en bloc resection of the uterus, both adnexal masses, pelvic peritoneum, rectosigmoid colon, as well as peritonectomy of both parieto-colic spaces, radical omentectomy, splenectomy, pelvic and para-aortic lymphadenectomy, right diaphragmatic stripping and en bloc resection of a plaque of tumor. The surgical pathology showed a low-grade papillary serous ovarian cancer affecting 27 out of 50 lymph nodes, extensive peritoneal carcinomatosis and infiltrating of all of the resected specimens.
Postoperative evolution was complicated by Serratia marcescens bacteremia and acute pancreatitis without severity criteria. The CT scan carried out after the patient was discharged showed a small amount of perihepatic ascites, right pleural effusion and residual calcified cardiophrenic and bilateral internal mammary lymph nodes. CA-125 value was 829 IU/mL. We suggested adjuvant chemotherapy with carboplatin, paclitaxel and bevacizumab. After a thorough discussion about the treatment options, the patient finally declined chemotherapy. The patient was offered hormone therapy with letrozole, which she finally accepted. A trimestral follow-up has been undertaken for the last 18 months, to date with no signs of progressive disease and stable tumor markers.
Discussion
Clinical management of women with low-grade ovarian cancer currently remains identical to that of other epithelial ovarian cancer histological subtypes. Undoubtedly, primary surgery is the backbone treatment of advanced epithelial ovarian cancer after the initial assessment by a team experienced in gynecological oncology. However, we must be aware that some subtypes as LGSOC, clear cell or mucinous ovarian cancer behave distinctly differently from HGSOC, and this should be taken into consideration when planning the treatment. Some evidence in the literature suggests that the role of surgery could be even more important in the initial management LGSOC. A retrospective trial reported that only 52% out of 112 stage II-IV LGSOC patients was clinically disease-free after completing the primary treatment, while in HGSOC this reached 70-80% [4] , probably due to lack of chemotherapy response. In addition, Crispens et al. described the association between optimal cytoreduction and overall survival (OS) [8] . Regarding systemic therapy, the standard of care consists of the administration of systemic chemotherapy with the combination of paclitaxel and carboplatin after the primary debulking surgery. In the specific context of LGSOC, two additional modalities have gained attention in the last years: the administration of bevacizumab and hormone therapy. As the number of patients with a diagnosis of LGSOC included in the Gynecologic Cancer Intergroup (GCIG) International Collaboration on Ovarian Neoplasms 7 (ICON7) and the Gynecologic Oncology Group study 0218 (GOG-0218) was low, data for bevacizumab in first line treatment is limited [9, 10] . In the context of recurrent disease, two retrospective studies from the MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center have demonstrated the activity of bevacizumab with or without chemotherapy in relapsed LGSOC or peritoneal cancer, with a clinical benefit in 77.5% and 73.3%, respectively [11, 12] . Among the two studies, bevacizumab monotherapy was administered to a total of 5 patients; 3 patients had stable disease, and 2 were not evaluable [11, 12] . Estrogen and progesterone are regulators of differentiation and growth of the ovaries that develop their biological activity through ER and progesterone receptors (PR). Compared with normal ovarian tissues, in ovarian cancer ER are upregulated, and PR expression is considered a good prognostic marker [13] . ERα is the isoform that, in ovarian cancer as in breast cancer, is most distinctly related to hormonal treatment sensitivity [13] . The Ovarian Tumor Analysis Consortium study included 2933 patients of different histological subtypes in order to analyze the prognostic role of hormonal receptors. However, with just 110 patients with LGSOC, no association between ER, PR and survival could be established [14] . Approximately 80% of LGSOC have high levels of ER and PR, suggesting these could respond to hormonal manipulation. Trials about the antiproliferative effects of hormonal therapy are currently lacking [15] . A recent retrospective trial examining the outcomes of hormone therapy with letrozole (received by 54.3% of patients), tamoxifen (28.6%), anastrozole (2.9%), leuprolide acetate (7.1%) or leuprolide acetate with either letrozole, tamoxifen or medroxyprogesterone acetate (7.2%) as maintenance treatment after platinum-based chemotherapy in stage II-IV LGSOC patients warranted a prospective trial, as the progression-free survival of those on treatment was 64.9 months compared with 26.4 months of those on observation (p<0.001). Nevertheless there was no statistically significant benefit in OS (115.7 vs 102.7 months; p=0.42) [16] . These results should be the seed of a new trial comparing hormonal therapy to platinum-based adjuvant chemotherapy. For now, the mainstay of treatment for recurrent disease should remain surgical management, as the tumor is relatively chemoresistant [17] . In the recent years, some trials targeting the RAS-RAF-MEK pathway have obtained promising results. However, these preliminary data have not been confirmed in randomized clinical trials.
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Commentary
The case report by Sánchez [4] . Surgery continues to play a major role in the management of low-grade serous carcinoma. This patient underwent a laparoscopy to determine resectability. Given the fact that neither host characteristics nor imaging modalities are reliable in predicting the extent of disease, this strategy is increasingly being practiced in triaging women to primary cytoreductive surgery versus neoadjuvant chemotherapy, albeit in the face of an ongoing controversy regarding the benefit of the latter approach [5, 6] . This controversy may be even more animated for women with this subtype in view of its relative chemoresistance and the reported low response rate in the neoadjuvant setting [7] . The [10] . Nevertheless, there is considerable information indicating activity of bevacizumab for low-grade serous carcinoma in the salvage setting [11, 12] [15] . We initially reported our experience with 64 women who received 89 separate hormonal therapies for recurrent low-grade serous carcinoma [16] . The overall response rate was 9%, the stable disease rate was 62%, and the median time to progression was 7.4 months. In addition, a retrospective study of hormonal therapy in the maintenance setting following primary platinumbased chemotherapy found a significant advantage in terms of progression-free survival compared to chemotherapy followed by observation -median, 65 versus 26 months, respectively [17] . Consequent 
